Intervention_Name,Category,Subcategory,Mechanism_of_Action,Target_Hallmark(s),Preclinical_Evidence_Summary,Lifespan_Extension_Pct,Species_Tested,Clinical_Trial_Phase,NCT_Number,Clinical_Endpoints,Clinical_Results_Summary,Safety_Profile,Key_Publication,Publication_Year,DOI_or_URL,Evidence_Grade,Notes
"Dasatinib + Quercetin (D+Q)",Senolytic,Tyrosine kinase + flavonoid combination,"Multi-kinase inhibitor (dasatinib targets Src/ephrin kinases in senescent preadipocytes) + flavonoid (quercetin inhibits PI3K/BCL-2/BCL-xL/serpines in senescent endothelial cells); synergistic SCAP network disruption",Cellular Senescence;Chronic Inflammation;Stem Cell Exhaustion,"~36% remaining lifespan extension in 24-month-old mice (Xu et al. 2018); reduced senescent cell burden in adipose, bone, brain, lung; improved cardiovascular function, exercise endurance, cognition",36,Mouse;Human (pilot),Phase 2,"NCT04063124;NCT02848131;NCT04685590;NCT06018467","CSF senescence markers; brain MRI; adipose SA-beta-gal; SASP factors (IL-6, MMP-9); bone resorption markers","First human senolytic proof-of-concept: reduced adipose p16INK4a and SA-beta-gal in DKD patients; STAMINA study safe with TNF-alpha reduction correlating with MoCA improvement; Phase 2 AD and osteoporosis trials active","Intermittent dosing well-tolerated; mild GI symptoms and fatigue most common; no serious AEs in pilot studies; 2024 concern re: kidney damage in acute nephropathy model; dasatinib oncology risks (thrombocytopenia, pleural effusion) reduced at senolytic doses","Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-1256",2018,10.1038/s41591-018-0092-9,B,"Typical dosing: Dasatinib 100mg + Quercetin 1000-1250mg for 3 consecutive days every 2-4 weeks (hit-and-run regimen)"
Fisetin,Senolytic,Natural flavonoid,"BCL-2/BCL-xL inhibition; PI3K/AKT/mTOR suppression; NF-kB suppression; p53 stabilization; SIRT1 activation; Nrf2 activation; most potent senolytic flavonoid identified in screening",Cellular Senescence;Chronic Inflammation,"~10% median and maximum lifespan extension in late-life treated mice (Yousefzadeh et al. 2018); selectively killed senescent HUVECs at 4-fold lower IC50 vs non-senescent; improved frailty and grip strength comparable to genetic p16+ clearance (2025)",10,Mouse;Human cells;C. elegans,Phase 2,"NCT03675724;NCT06431932;NCT04537299;NCT07195318;NCT06133634","Circulating IL-6 and SASP markers; frailty index; gait speed; grip strength; clinical severity in COVID-19","AFFINITY trial: well-tolerated with mixed SASP marker results; Mayo Clinic long-COVID: 64% of 44 fisetin-treated patients (of 536 total) reported significant symptom alleviation; TROFFi trial ongoing in frail breast cancer survivors","Generally well-tolerated; mild GI symptoms; GRAS status as dietary supplement; bioavailability is a significant challenge (extensive first-pass metabolism, low aqueous solubility); inhibits CYP2C8 and CYP3A4 in vitro","Yousefzadeh MJ et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28",2018,10.1016/j.ebiom.2018.09.015,B,"Natural flavonoid found in strawberries, apples, persimmons; bioavailability remains the key translational challenge"
"Navitoclax (ABT-263)",Senolytic,BH3 mimetic,"Small-molecule BH3 mimetic; inhibits BCL-2/BCL-xL/BCL-w with Ki < 1 nM; displaces pro-apoptotic BH3-only proteins (BIM, BAD, PUMA); triggers BAX/BAK oligomerization and cytochrome c release; senescent cells preferentially killed due to elevated BCL-2/BCL-xL",Cellular Senescence;Stem Cell Exhaustion,"Selectively killed senescent HUVECs and IMR90 fibroblasts; rejuvenated aged hematopoietic stem cells (Chang et al. 2016); galactose-modified Nav-Gal reduced off-target thrombocytopenia; topical application on aged mouse skin effective (Dec 2024); effective in glioma/DMG models (2025)",Not reported,Mouse;Human cells,No aging trials,"N/A","N/A (oncology endpoints only in existing trials)","No dedicated aging/longevity clinical trials; extensive oncology history (CLL, lymphoma); 2024-2025 focus on topical/local delivery to avoid systemic thrombocytopenia; prodrug strategies (Nav-Gal, PZ-15227) in development","Major dose-limiting toxicity: thrombocytopenia (BCL-xL essential for platelet survival); neutropenia less common; nausea, diarrhea, fatigue from oncology trials; topical delivery may circumvent systemic toxicity","Zhu Y et al. Identification of a novel senolytic agent navitoclax targeting the Bcl-2 family. Aging Cell. 2016;15(3):428-435",2016,10.1111/acel.12445,C,"Thrombocytopenia is the primary obstacle to aging indication; local/topical delivery and prodrug approaches (Nav-Gal) are key strategies"
"UBX1325 (Foselutoclax)",Senolytic,BCL-xL inhibitor (intravitreal),"Small-molecule BCL-xL inhibitor designed for intravitreal injection; eliminates senescent retinal pigment epithelial cells, endothelial cells, and pericytes; reduces SASP factors (VEGF, IL-6, IL-8) in diabetic retina",Cellular Senescence;Chronic Inflammation,"Selectively killed senescent human RPE cells, endothelial cells, Muller glia in vitro; reduced senescent cell burden and SASP in mouse retinal degeneration models; single injection provided weeks of durability; no retinal toxicity in rabbit/NHP studies",N/A,Mouse;Rabbit;Non-human primate;Human,Phase 2b,"NCT04537884;NCT04857996","ETDRS visual acuity letters gained; central subfield thickness (OCT); durability of effect; safety","Phase 2b ASPIRE: 5.6 more ETDRS letters vs sham at week 48 (95% CI: -1.5 to 12.7); statistically significant and clinically meaningful; 48-week durability from single injection; BEHOLD Phase 2 did not meet primary endpoint at 24 weeks","No dose-limiting toxicities in Phase 1; no TEAEs leading to discontinuation in Phase 2b; no systemic thrombocytopenia (local delivery avoids systemic BCL-xL inhibition); injection-related AEs only (conjunctival hemorrhage, eye pain)","UBX1325 ASPIRE Phase 2b results. NEJM Evidence",2024,https://www.nejm.org/doi/full/10.1056/NEJMoa2310065,A,"Unity Biotechnology secured $55M Series C (2024); intravitreal delivery avoids systemic BCL-xL inhibition toxicity; BEHOLD failed but ASPIRE succeeded"
"Rapamycin (Sirolimus)",mTOR Inhibitor,Macrolide mTORC1 inhibitor,"Binds FKBP12; rapamycin-FKBP12 complex inhibits mTORC1 FRB domain; suppresses S6K1/S6K2 (protein synthesis); activates autophagy (ULK1 de-repression); activates TFEB (lysosomal biogenesis); reduces SASP (senomorphic); modulates immune function at low doses",Deregulated Nutrient-Sensing;Disabled Macroautophagy;Loss of Proteostasis;Cellular Senescence;Chronic Inflammation,"9-26% lifespan extension dose-dependent in ITP mice (Harrison 2009, Miller 2014); 36.6% with acarbose combo; short-term treatment in middle-aged mice extended lifespan (Bitto 2016); improved cardiac function in dogs; Oxford study: reduces senescent cells in humans","9-26 (monotherapy); 36.6 (with acarbose)",Mouse;Dog;Human,Phase 2,"NCT04488601;NCT05237687","Epigenetic age; immune function; lean tissue mass; pain scores; emotional well-being; visceral fat; bone density","PEARL trial (48-week RCT, 114 adults 50-85): safe and well-tolerated; women on 10mg weekly improved lean tissue and reduced pain; 5mg improved emotional well-being; caveat: compounded rapamycin had ~1/3 bioavailability of commercial formulation","Low-dose/intermittent: mouth ulcers most common; may enhance certain immune responses; manageable hyperlipidemia; PEARL confirmed safety at 5-10mg weekly; standard dose risks: immunosuppression, impaired wound healing, stomatitis, insulin resistance","Harrison DE et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395",2009,10.1038/nature08221,B,"Most robustly replicated pharmacological lifespan extension in mammals; 2025 review notes no clear clinical evidence of translation yet; Dog Aging Project TRIAD (580 dogs) ongoing"
"Everolimus (RAD001)",mTOR Inhibitor,Synthetic rapalog,"FKBP12-mediated mTORC1 inhibition identical to rapamycin mechanism; improved oral bioavailability; shorter half-life (~30h vs ~60h for rapamycin)",Deregulated Nutrient-Sensing;Disabled Macroautophagy;Chronic Inflammation,"Preclinical aging data mirrors rapamycin; primary contribution from clinical immune aging studies",Not reported,Mouse;Human,Phase 2,"NCT01227135;NCT05835999","Influenza vaccine antibody titers; PD-1+ T cell reduction; respiratory tract infection incidence","Mannick 2014 LANDMARK: 218 healthy older adults (>=65); 0.5mg/day or 5mg weekly enhanced influenza vaccine response by ~20%; reduced PD-1+ CD4/CD8 T cells; 2018 study with RTB101: 264 elderly, reduced RTIs by 30.6%; EVERLAST trial ongoing","Well-tolerated at low doses; mouth ulcers (2-10% at low doses); no significant immunosuppression at low doses; mild hyperlipidemia; full oncology doses have rapamycin-like side effects","Mannick JB et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179",2014,10.1126/scitranslmed.3009892,B,"Groundbreaking: first demonstration that mTOR inhibitor improves immune function in elderly rather than suppressing it"
RTB101,mTOR Inhibitor,Catalytic TORC1 inhibitor,"Catalytic (not allosteric) inhibitor of TORC1 kinase domain; derived from dactolisib (BEZ235); proposed preferential mTORC1 inhibition while sparing mTORC2 to avoid insulin resistance",Deregulated Nutrient-Sensing;Disabled Macroautophagy,"Limited independent preclinical aging data; clinical development focused",Not reported,Human,Phase 3 (failed),"NCT03693612","Incidence of laboratory-confirmed respiratory tract infections; immune markers","Phase 2b: RTB101 10mg + everolimus 0.5mg reduced RTIs by 30.6% (p=0.008) in 264 elderly; Phase 3 PROTECTOR: RTB101 monotherapy (10mg daily) FAILED in ~652 elderly -- did not reduce respiratory infections; resTORbio stock dropped ~75%","Tolerable in Phase 2b combination; Phase 3 monotherapy safety acceptable but no efficacy demonstrated","Mannick JB et al. Targeting the biology of ageing with mTOR inhibitors. Lancet Healthy Longev. 2021;2(5):e250-e262",2021,10.1016/S2666-7568(21)00062-3,A,"Phase 3 failure; resTORbio acquired; investigators (Mannick, Schor) co-founded Tornado Therapeutics (2022) for refined mTOR strategies"
"NMN (Nicotinamide Mononucleotide)",NAD+ Precursor,Direct NAD+ biosynthetic precursor,"Direct precursor to NAD+ via single NMNAT enzymatic step; NAD+ serves as redox cofactor, sirtuin substrate (SIRT1-7), PARP substrate for DNA repair, and CD38/CD157 substrate; restores age-depleted NAD+ levels",Genomic Instability;Mitochondrial Dysfunction;Deregulated Nutrient-Sensing,"12-month NMN suppressed age-related weight gain, enhanced energy metabolism, improved insulin sensitivity in mice (Mills 2016); improved vascular endothelial function; no published significant lifespan extension in mice",Not reported,Mouse;Human,Phase 1/2,"NCT03151239;NCT05594108;NCT07144527","Muscle insulin sensitivity; blood NAD+ metabolites; walking speed; sleep quality; metabolic parameters","Yoshino 2021: 250mg/day x 10 weeks improved muscle insulin sensitivity in prediabetic women; Feb 2025: liposomal NMN increased NAD+; 2024 (n=60): improved walking speed and sleep; meta-analysis of 8 RCTs: no significant benefit on fasting glucose, insulin, HbA1c, or lipids","Generally well-tolerated at doses up to 1200mg/day; no SAEs; mild GI symptoms (nausea, bloating), headache; long-term safety data (>12 weeks) limited; theoretical cancer concern re: fueling cancer cell metabolism","Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229",2021,10.1126/science.abe9985,B,"Meta-analysis shows minimal benefits for sarcopenia/muscle in adults over 60; MIB-626 (crystalline NMN) Phase 2 active"
"NR (Nicotinamide Riboside)",NAD+ Precursor,Indirect NAD+ precursor,"NAD+ precursor requiring NRK1/NRK2 conversion to NMN then NMNAT conversion to NAD+; one additional enzymatic step vs NMN; crosses membranes via ENT channels; established oral bioavailability",Genomic Instability;Mitochondrial Dysfunction;Deregulated Nutrient-Sensing,"NR replenished NAD+ in aged mice; improved mitochondrial and stem cell function; enhanced muscle regeneration; modestly extended lifespan (Zhang 2016); improved cardiac function in dilated cardiomyopathy model",Modest (not quantified),Mouse;Human,Phase 2,"NCT02921659;NCT03151239","Blood NAD+ metabolites; PBMC mitochondrial respiration; cardiac function; cognition; epigenetic age","Consistently raises blood NAD+ in humans but NOT consistently translated to clinical endpoint improvements; MCI trial: increased NAD+ but did NOT alter cognition; reduced epigenetic age (PhenoAge, GrimAge); Long-COVID RCT (2000mg/day, 24wk, 58 pts); NR for HF: biomarkers up but no clinical benefit","Very well-tolerated at doses up to 2000mg/day; no SAEs; no hepatotoxicity signal; mild GI symptoms; less flushing than niacin","Zhang H et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science. 2016;352(6292):1436-1443",2016,10.1126/science.aaf2693,B,"The NAD+ paradox: blood NAD+ increases reliably but clinical benefits are inconsistent; 2025 assessment: minimal benefits for muscle mass/function in adults over 60"
CD38 Inhibitors,NAD+ Modulator,NADase inhibitor,"CD38 is the primary NADase in mammalian tissues; expression increases with age driven by inflammaging; responsible for majority of age-related NAD+ decline; inhibition preserves NAD+ by preventing degradation (upstream of NMN/NR supplementation approach)",Mitochondrial Dysfunction;Chronic Inflammation;Deregulated Nutrient-Sensing,"CD38 KO mice protected from metabolic dysfunction (Camacho-Pereira 2016); 78c (CD38 inhibitor) reversed age-related NAD+ decline, improved exercise capacity and metabolic parameters (Tarago 2018); restored cardiac and metabolic function (Chini 2020)",Not reported,Mouse,Preclinical,N/A,N/A,"No dedicated CD38 inhibitor clinical trials for aging; anti-CD38 antibodies (daratumumab) approved for myeloma but cause immune suppression; small-molecule 78c and analogs in preclinical development; combination with NMN/NR explored preclinically","Anti-CD38 antibodies cause profound immunosuppression (not suitable for aging); small-molecule inhibitors (78c) safety profile under evaluation; conceptually targets root cause of NAD+ decline rather than supplementation","Camacho-Pereira J et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction. Cell Metab. 2016;23(6):1127-1139",2016,10.1016/j.cmet.2016.05.002,D,"Conceptually upstream of NMN/NR: maintains NAD+ by preventing degradation rather than supplying more precursors"
Metformin,Nutrient-Sensing Modulator,Biguanide AMPK activator,"AMPK activation via mitochondrial complex I inhibition; indirect mTORC1 inhibition; promotes autophagy; anti-inflammatory (reduces NF-kB, IL-6, TNF-alpha); gut microbiome modulation (increases Akkermansia); may slow epigenetic aging; reduces insulin/IGF-1 signaling",Deregulated Nutrient-Sensing;Chronic Inflammation;Mitochondrial Dysfunction;Disabled Macroautophagy;Dysbiosis,"~5-6% lifespan extension in mice (Martin-Montalvo 2013); epidemiological: diabetics on metformin lived 15% longer than non-diabetic controls (Bannister 2014); MILES pilot showed geroprotective gene expression changes","5-6 (mice)",Mouse;Human (epidemiological),Phase 3,"NCT02432287","Composite: CVD, cancer, dementia, death; gait speed; grip strength; epigenetic age; inflammatory markers","TAME trial enrolling 3000 non-diabetic adults 65-79 (6-year); MILES pilot positive for gene expression; Nature Signal Transduction 2024: decelerates aging clock biomarkers; 2025 review: emerging uncertainty; generally NOT demonstrated anticipated benefits in non-diabetic RCTs","Extremely well-characterized over 60+ years (~150M patients); GI symptoms (20-30%, improved with ER); vitamin B12 deficiency; lactic acidosis extremely rare (2-9/100K patient-years); no immunosuppression; ~$4/month generic","Barzilai N et al. Metformin as a Tool to Target Aging. Cell Metab. 2016;23(6):1060-1065",2016,10.1016/j.cmet.2016.05.011,B,"TAME now under ARPA-H framework; Eli Lilly planning TAME-like study with GLP-1 agonist; uniquely accessible at ~$4/month"
"Yamanaka Factors (OSK/OSKM)",Epigenetic Reprogramming,Transcription factor-based partial reprogramming,"Oct4, Sox2, Klf4 (OSK, omitting oncogene c-Myc) transiently expressed via AAV; resets epigenome to younger state without full dedifferentiation; reverses DNA methylation age; restores youthful gene expression while maintaining cell identity",Epigenetic Alterations;Telomere Attrition;Stem Cell Exhaustion;Loss of Proteostasis,"AAV-OSK in 124-week-old mice: 109% extension of median remaining lifespan (PubMed: 38381405); Cell 2025 (Belmonte): reversed mesenchymal drift; bioRxiv 2025: single-factor approach demonstrated",109 (remaining lifespan),Mouse,Preclinical,N/A,"N/A (Altos Labs planning human safety testing August 2025; Retro Bio first trial by end 2025)","No human trials completed; Altos Labs ($3B) planning human safety testing August 2025; Retro Biosciences ($1B Series A) first human trial in Australia by end 2025; Turn Bio ($300M HanAll deal) IND-enabling for TRN-001 targeting 2026","Major concern: tumorigenesis risk; c-Myc is oncogene (hence OSK without M); even OSK carries risk if expression not precisely controlled; chemical reprogramming alternatives being explored as safer approach","AAV-OSK lifespan extension study. PubMed: 38381405",2024,https://pubmed.ncbi.nlm.nih.gov/38381405/,C,"Largest mammalian lifespan extension by any intervention; $3B+ industry investment (Altos Labs, Retro Bio, Turn Bio, Life Bio, NewLimit, Shift Bio)"
Semaglutide,GLP-1 Agonist,GLP-1 receptor agonist,"GLP-1 receptor agonist and incretin mimetic; glucose-dependent insulin secretion; appetite suppression; reduces systemic inflammation (CRP, IL-6, TNF-alpha); modulates immune cell function; potential direct CNS effects via brain GLP-1 receptors; MACE reduction independent of weight loss",Chronic Inflammation;Deregulated Nutrient-Sensing;Altered Intercellular Communication,"Limited preclinical aging-specific data; clinical evidence emerging for aging-relevant endpoints; HIV study: slowed DNA methylation aging (PCGrimAge -3.1yr, PhenoAge -4.9yr, DunedinPACE -9%)",N/A,Human,Phase 3,"NCT03574597;NCT04788511","MACE-3; all-cause mortality; KCCQ scores; epigenetic aging clocks; Alzheimer's endpoints (EVOKE/EVOKE+ ongoing)","SELECT: 20% MACE reduction (HR 0.80, p<0.001) in 17604 adults; 19% all-cause death reduction; STEP-HFpEF: improved symptoms and function; HIV epigenetic aging: remarkable clock reversal; EVOKE/EVOKE+ Phase 3 for Alzheimer's underway","Well-established from millions of patients; nausea, vomiting, diarrhea (typically transient); rare pancreatitis; thyroid C-cell tumors in rodents (not confirmed in humans); muscle mass loss with weight loss is concern for older adults","Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232",2023,10.1056/NEJMoa2307563,B,"Nature Biotechnology 2025: Are GLP-1s the first longevity drugs?; no healthy-population longevity trials yet; most evidence from metabolically unhealthy cohorts"
Tirzepatide,GLP-1 Agonist,Dual GIP/GLP-1 receptor agonist,"Dual GIP/GLP-1 receptor agonist; activates both incretin receptor systems; potentially broader metabolic and anti-inflammatory effects than GLP-1 agonism alone",Chronic Inflammation;Deregulated Nutrient-Sensing;Altered Intercellular Communication,"Emerging aging-relevant data; similar class effects expected to semaglutide; cardiovascular and metabolic protection data from SURPASS and SURMOUNT programs",N/A,Human,Phase 3 (metabolic),N/A,Cardiovascular outcomes; metabolic parameters; weight loss,"No dedicated aging/longevity trials; cardiovascular and metabolic protection data accumulating from SURPASS/SURMOUNT trial programs; similar anti-inflammatory class effects expected","Well-established safety from SURPASS/SURMOUNT trials; GI side effects (nausea, diarrhea); similar profile to semaglutide","SURPASS and SURMOUNT trial program publications",2023,https://www.nejm.org/doi/full/10.1056/NEJMoa2206038,B,"No dedicated aging trials; potential for broader effects than semaglutide due to dual receptor mechanism"
"Urolithin A (Mitopure)",Mitochondrial Therapy,Mitophagy activator,"Natural gut metabolite from ellagitannins; potent PINK1/Parkin mitophagy pathway activator; triggers selective clearance of damaged mitochondria; stimulates compensatory mitochondrial biogenesis; improves cellular energy production and reduces oxidative stress",Mitochondrial Dysfunction;Disabled Macroautophagy;Chronic Inflammation,"25+ registered human trials; $50M+ R&D; 80+ global patents; 12% muscle strength improvement over 4 months (PMC9133463); MitoImmune 2025: expanded naive CD8+ T cells demonstrating immune rejuvenation",N/A,Mouse;Human,Phase 2/3,"NCT03464500;NCT04160312","Muscle strength and endurance; mitochondrial biomarkers; naive CD8+ T cell expansion; brain health (CLARITY study, 650 pts)","ATLAS Phase 2: improved mitochondrial biomarkers and leg muscle strength at 500mg; elderly study: improved muscle endurance and grip strength; MitoImmune (Nature Aging 2025): 1000mg/day x 4 weeks expanded naive CD8+ T cells; CLARITY (650 pts, brain health) completing March 2026","Well-tolerated across multiple clinical trials; no significant AEs at doses up to 1000mg/day; GRAS status; commercially available as supplement (Mitopure)","Liu S et al. Urolithin A in middle-aged adults. JAMA Netw Open. 2022;5(1):e2144279",2022,10.1001/jamanetworkopen.2021.44279,A,"One of most accessible longevity compounds with clinical evidence; commercially available; CLARITY (650 pts) is largest mitophagy enhancer trial for neurological endpoints"
"Elamipretide (SS-31/FORZINITY)",Mitochondrial Therapy,Cardiolipin-targeting peptide,"Mitochondria-targeting tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2); selectively concentrates in inner mitochondrial membrane; binds cardiolipin; stabilizes cristae structure; reduces ROS at complex III; enhances ATP production; optimizes cytochrome c interaction",Mitochondrial Dysfunction;Genomic Instability,"Reverses age-related redox stress; improves exercise tolerance in aged mice; restores mitochondrial function across tissue types",N/A,Mouse;Human,FDA Approved (Barth syndrome),N/A,"Barth syndrome (TAZPOWER); heart failure (PROGRESS-HF); primary mitochondrial myopathy (MMPOWER-3); AMD (ReCLAIM)","FDA approved September 2025 as FORZINITY for Barth syndrome under accelerated approval; first FDA-approved mitochondria-targeting peptide therapy; creates pathway for broader aging-related applications","Safety data from multiple clinical trials; generally well-tolerated; injection site reactions common (subcutaneous administration); specific profile varies by indication and dosing","Szeto HH. First-in-class cardiolipin-protective compound. Br J Pharmacol. 2014;171(8):2029-2050",2014,10.1111/bph.12461,A,"FDA approval for Barth syndrome (Sept 2025) establishes regulatory precedent for mitochondria-targeting therapies; aging-related repurposing potential"
Taurine,Emerging Intervention,Semi-essential amino acid,"Reduces cellular senescence; protects telomerase activity; enhances mitochondrial function; reduces DNA damage; attenuates inflammaging; modulates oxidative stress; identified as fundamental aging driver by Singh et al. 2023 Science",Cellular Senescence;Telomere Attrition;Mitochondrial Dysfunction;Chronic Inflammation;Genomic Instability,"Life expectancy increased 12% (female) and 10% (male) in mice; life expectancy at 28 months increased 18-25% (~7-8 human year equivalent); C. elegans lifespan extended 10-23%; lower taurine correlated with age-related diseases in humans","10-12 (mice); 10-23 (C. elegans)",Mouse;C. elegans;Human (correlation),No aging RCTs,N/A,"N/A (observational and mechanistic studies ongoing)","No large-scale RCTs for aging endpoints; observational data showing lower taurine correlated with age-related diseases; 2024 follow-up noted large interindividual variation and inconsistencies in human data","Long history of safe use as supplement; present in energy drinks and foods; no significant toxicity at standard doses; upper limit not well-established for chronic high-dose use","Singh P et al. Taurine deficiency as a driver of aging. Science. 2023;380(6649):eabn9257",2023,https://pubmed.ncbi.nlm.nih.gov/37289866/,C,"Landmark 2023 Science paper; widely available as supplement; no RCTs yet; large interindividual variation noted"
"GlyNAC (Glycine + N-Acetylcysteine)",Emerging Intervention,Glutathione precursor combination,"Glycine + NAC serve as precursors for glutathione (GSH) synthesis; restores age-depleted glutathione levels; improves mitochondrial function and fuel oxidation; reduces oxidative stress; lowers inflammation; improves genomic damage markers",Mitochondrial Dysfunction;Chronic Inflammation;Genomic Instability;Loss of Proteostasis,"Research led by Sekhar lab at Baylor College of Medicine; 36-week pilot RCT: GlyNAC reversed multiple age-associated defects; stopping for 12 weeks caused defects to return; improved glutathione, oxidative stress, mitochondrial function, inflammation",N/A,Human,Phase 2,"NCT04740034","Glutathione levels; oxidative stress (TBARS, F2-isoprostanes); mitochondrial fatty acid oxidation; gait speed; grip strength; cognition; insulin resistance; body composition","Remarkably broad improvements: corrected glutathione deficiency, reduced oxidative stress, improved mitochondrial function, inflammation, insulin resistance, endothelial function, body composition, cognition, strength, gait speed, exercise capacity; benefits reversed upon cessation","Safe and well-tolerated; both glycine and NAC have extensive safety records; NAC is FDA-approved (Mucomyst); no significant AEs reported","Kumar P et al. GlyNAC in older adults. Clin Transl Med. 2021;11(3):e372",2021,10.1002/ctm2.372,B,"Benefits reversed upon stopping supplementation suggesting ongoing use necessary; Alzheimer's implications through glutathione restoration and oxidative stress reduction"
Spermidine,Autophagy Activator,Natural polyamine,"Most potent known autophagy inducer; autophagy induction via eIF5A hypusination; EP300/CBP acetyltransferase inhibition leading to deacetylation of autophagy-related proteins; TFEB activation; NF-kB suppression and anti-inflammatory effects",Disabled Macroautophagy;Loss of Proteostasis;Chronic Inflammation;Deregulated Nutrient-Sensing,"Cardioprotection and lifespan extension in mice (Eisenberg 2016); spermidine intake associated with reduced cardiovascular mortality in observational studies; cognitive effects inconsistent across studies",Not reported,Mouse;Drosophila;Human,Phase 2,"NCT03094546;NCT05421546","Memory performance (mnemonic similarity task); cardiac diastolic function; autophagy markers; inflammatory markers; cardiometabolic endpoints (POLYCAD trial, 187 patients)","SmartAge: trend toward improved memory, modest effect sizes; cognitive effects inconsistent (100 pts, 12 months: no benefit); 40mg/day safe and tolerable in healthy older men over 28 days; POLYCAD trial (187 elderly CAD patients) recruitment completed August 2025","40mg/day demonstrated safety and tolerability; natural dietary component (wheat germ, soybeans, aged cheese); no significant AEs in published studies","Eisenberg T et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med. 2016;22(12):1428-1438",2016,10.1038/nm.4222,B,"Natural compound found in wheat germ, soybeans, aged cheese; cognitive effects remain inconsistent across trials"
"Alpha-Ketoglutarate (AKG)",Emerging Intervention,TCA cycle metabolite / CR mimetic,"Key TCA cycle intermediate; caloric restriction mimetic; cofactor for TET DNA demethylases and Jumonji histone demethylases (epigenetic regulation); mTOR modulation; HIF-1alpha regulation; required for prolyl hydroxylase activity (collagen synthesis)",Epigenetic Alterations;Deregulated Nutrient-Sensing;Mitochondrial Dysfunction,"Ca-AKG reduced biological age by average 8 years over 7 months in pilot human study; 2025 mouse studies: improved memory formation and neuroprotection via mTOR modulation",Not reported,Mouse;Human,Pilot / Phase 2,"NCT05706389;NCT07114536","Biological age (TruAge DNA methylation clock); blood biomarkers; self-reported health; ABLE trial: 1g Ca-AKG for 6 months in 120 adults aged 40-60","Pilot: average 8-year biological age reduction (TruAge clock) over 7 months (uncontrolled, n=42); ABLE trial (Singapore, 120 adults 40-60) is most rigorous AKG aging trial to date; 2025 mouse neuroprotection studies positive","Ca-AKG generally well-tolerated; natural metabolite present in all cells; no significant safety concerns at supplementation doses; available as supplement","Demidenko O et al. Rejuvant CaAKG biological age reduction. Aging (Albany NY). 2021;13(7):9711-9728",2021,10.18632/aging.202913,B,"Pilot study limitations: small sample size (n=42), single-arm, no placebo; ABLE trial in Singapore will provide more rigorous data"
Klotho Gene Therapy,Gene Therapy,AAV-delivered anti-aging gene,"Klotho protein: FGF23 co-receptor (phosphate/calcium metabolism); anti-inflammatory (reduces NF-kB, TNF-alpha); anti-fibrotic (inhibits TGF-beta); neuroprotective (enhances synaptic plasticity); anti-oxidant (enhances SOD2, catalase); Wnt signaling modulator",Chronic Inflammation;Stem Cell Exhaustion;Altered Intercellular Communication;Genomic Instability,"AAV-Klotho prolonged mouse lifespan by 19.7% (Molecular Therapy 2025); mice lived 15-20% longer with better physical performance, larger muscle fibers, less fibrosis; reversed astrocyte depletion, increased neurons and microglia",19.7,Mouse;Human (dementia patients - cognitive improvement reported),Early clinical,N/A,"Lifespan; physical performance; muscle fiber size; cognitive scores; combined Klotho + Follistatin trial initiated for healthy adults","Dementia patients showed improved cognitive scores post-therapy; combined Klotho + Follistatin clinical trial for healthy adults initiated; Minicircle Bio expects clinical stage in 2026","AAV vector delivery carries standard gene therapy risks (immunogenicity, insertional mutagenesis); Klotho overexpression appears well-tolerated preclinically; long-term effects of sustained Klotho elevation unknown","Klotho gene therapy lifespan study. Molecular Therapy. 2025",2025,https://doi.org/10.1016/j.ymthe.2025.01.001,C,"Three new patents filed; Minicircle Bio targeting clinical stage 2026; combined Klotho + Follistatin trial ongoing"
Follistatin Gene Therapy,Gene Therapy,AAV-delivered myostatin antagonist,"Follistatin binds and neutralizes TGF-beta superfamily members (activin, myostatin); by inhibiting myostatin (negative regulator of muscle growth) promotes muscle growth/maintenance, reduces fibrosis, improves metabolic function and physical performance",Stem Cell Exhaustion;Altered Intercellular Communication;Loss of Proteostasis,"Intranasal AAV delivery of follistatin extended mouse lifespan by ~30%; improved physical performance; demonstrated synergy with Klotho gene therapy",30,Mouse,Early clinical,N/A,"Lifespan; physical performance; muscle mass; combined with Klotho in healthy adult trial","Combined with Klotho in clinical trial for healthy adults (ongoing); prior clinical experience with follistatin gene therapy in muscular dystrophy provides safety data","Prior muscular dystrophy clinical experience provides baseline safety data; AAV vector delivery carries standard gene therapy risks; long-term overexpression effects unknown","Intranasal AAV-Follistatin lifespan study",2024,N/A,C,"~30% lifespan extension is among largest for single-gene interventions; synergy with Klotho gene therapy demonstrated"
SIRT6 Overexpression,Gene Therapy,NAD-dependent deacetylase overexpression,"SIRT6 is NAD-dependent deacetylase critical for: DNA DSB repair (NHEJ and HR); glucose homeostasis; NF-kB RelA/p65 deacetylation (inflammation reduction); H3K9 deacetylation at telomeres (telomere maintenance); heterochromatin stability",Genomic Instability;Telomere Attrition;Chronic Inflammation;Deregulated Nutrient-Sensing,"SIRT6 overexpression: 30% lifespan increase in both sexes in transgenic mice (Cohen lab, Bar-Ilan University); preserved hepatic glucose output; improved NAD+ synthesis; suppresses LINE-1 retrotransposon activity",30,Mouse,Preclinical,N/A,N/A,"GF-1002: SIRT6 gene variant enriched in centenarians with demonstrated preclinical adipogenic, anti-fibrotic, and anti-tumoral properties; TripleHelix pursuing clinical development","SIRT6 overexpression appears safe in transgenic models; no adverse effects reported; tumor suppressor function suggests potential anti-cancer benefit","Cohen lab SIRT6 transgenic lifespan studies. Bar-Ilan University",2023,N/A,C,"GF-1002 variant enriched in centenarians; TripleHelix pursuing clinical development; tumor suppressor function is a safety advantage"
TERT Gene Therapy,Gene Therapy,Telomerase reverse transcriptase delivery,"TERT is catalytic subunit of telomerase; extends telomeres increasing replicative capacity; improves tissue regeneration; reduces telomere-driven senescence; extra-telomeric functions as transcription factor: neurogenesis, Wnt/beta-catenin modulation, SASP suppression",Telomere Attrition;Cellular Senescence;Stem Cell Exhaustion;Genomic Instability,"Blasco lab: AAV-TERT extended mouse lifespan without increasing cancer incidence (critical safety finding); TERT also functions as transcription factor affecting neurogenesis, Wnt signaling, senescence suppression",Not reported (lifespan extended),Mouse,Preclinical,N/A,N/A,"No human clinical trials; preclinical only; Bioviva (controversial self-experimentation) claimed telomere elongation but not peer-reviewed","AAV-TERT did not increase cancer incidence in mice (Blasco lab) addressing primary safety concern; standard AAV gene therapy risks apply; long-term effects unknown","Blasco lab. AAV-TERT lifespan extension without cancer increase",2012,N/A,D,"Key finding: no cancer increase despite telomerase activation; TERT has important extra-telomeric transcription factor functions"
"H-151 (STING Inhibitor)",Inflammaging Target,cGAS-STING pathway inhibitor,"Small-molecule STING inhibitor; blocks cGAS-STING-driven sterile inflammation; STING normally activated by cytosolic DNA from mitochondrial damage, nuclear envelope rupture, genomic instability; drives type I interferon and NF-kB-mediated chronic inflammation",Chronic Inflammation;Genomic Instability;Mitochondrial Dysfunction,"H-151 improved muscle strength and memory in aged mice; reduced microgliosis (brain inflammation); Nature 2023: cGAS-STING drives ageing-related neuroinflammation; PNAS 2025: noncanonical cGAS-STING pathway drives cellular/organismal aging",Not reported,Mouse,Preclinical,N/A,N/A,"No dedicated aging clinical trials; multiple pharma companies developing STING inhibitors for inflammatory/autoimmune diseases (potential repurposing); novel indole STING inhibitors and STING degraders (PROTACs) in development","Safety profile for long-term use unknown; concern about compromising antiviral and antitumor immunity with chronic STING inhibition; musculoskeletal disease applications being explored","cGAS-STING drives ageing-related inflammation and neurodegeneration. Nature. 2023",2023,N/A,D,"cGAS-STING is a central inflammaging mechanism; STING inhibition is a novel therapeutic strategy; musculoskeletal applications being explored"
Plasma Exchange / Therapeutic Plasmapheresis,Parabiosis Approach,Blood factor dilution/replacement,"Based on heterochronic parabiosis; Conboy hypothesis: benefits come primarily from dilution/neutralization of pro-aging factors in old blood rather than young rejuvenating factors; neutral blood exchange with saline-albumin shows rejuvenation; removes age-elevated harmful proteins",Altered Intercellular Communication;Chronic Inflammation;Stem Cell Exhaustion,"Neutral blood exchange (saline-albumin) in old mice showed substantial rejuvenation supporting dilution hypothesis; heterochronic parabiosis rejuvenates brain, muscle, liver, bone in old mice; Alkahest developing plasma fraction therapeutics",Not reported,Mouse;Human,Phase 2,"N/A (Alkahest GRF6019 for AD; Lyfspn planning trials)","Cognitive function; tissue rejuvenation biomarkers; Alzheimer's disease endpoints (Alkahest GRF6019)","Alkahest: GRF6019 Phase 2 for Alzheimer's; Lyfspn planning therapeutic plasmapheresis trials; neutral blood exchange experiments support dilution hypothesis; no large-scale aging RCTs completed","Plasma transfusion: allergic reactions, infection transmission, TRALI risk; plasmapheresis is established medical procedure with known safety profile; Conboy approach (dilution) may be safer than young plasma transfusion","Conboy I and Conboy M. Neutral blood exchange experiments",2020,N/A,B,"Debate: young factors vs dilution of aged factors; Conboy dilution hypothesis has significant therapeutic implications; established plasmapheresis procedure"
GDF11,Young Blood Factor,Growth differentiation factor supplementation,"Growth Differentiation Factor 11; member of TGF-beta superfamily; proposed as rejuvenating circulating factor that declines with age; attenuates age-related tissue degeneration; effects on vasculature, brain, bone reported",Altered Intercellular Communication;Stem Cell Exhaustion,"GDF11 attenuates age-related knee degeneration in mice; controversy: some studies show GDF11 hinders muscle regeneration by inhibiting satellite cell activation while others show beneficial effects on vasculature, brain, bone",Not reported,Mouse,Preclinical,N/A,N/A,"Elevian (Lee Rubin, Harvard) developing GDF11-based therapies; primarily preclinical; significant controversy over net effects; dose-dependent and tissue-specific effects may explain discrepancies","Safety in humans not established; GDF11's effects on muscle regeneration are controversial (may inhibit satellite cell activation); dose-dependent effects complicate safety assessment","Sinha M et al. Restoring systemic GDF11 levels reverses age-related dysfunction. Science. 2014;344(6184):649-652",2014,10.1126/science.1251152,D,"Significant scientific controversy: beneficial vs harmful effects on muscle; Elevian (Harvard) pursuing development; dose and tissue specificity may be key"
AA-20,Autophagy Activator,Novel TFEB-dependent autophagy enhancer,"Novel small-molecule autophagy enhancer; activates TFEB/HLH-30-dependent autophagy without inhibiting mTORC1; promotes lysosomal biogenesis and autophagy gene expression; mechanistically distinct from rapamycin",Disabled Macroautophagy;Loss of Proteostasis,"Extends C. elegans lifespan without mTORC1 inhibition (PNAS 2025); significant because it separates autophagy enhancement from mTOR inhibition, potentially avoiding metabolic and immunosuppressive side effects of rapamycin",Not reported,C. elegans,Preclinical,N/A,N/A,"Preclinical only (C. elegans); no mammalian lifespan data yet; represents a new class of mTOR-independent autophagy activators",Unknown; early-stage compound,"AA-20 autophagy enhancer. PNAS. 2025",2025,N/A,D,"Key advance: separates autophagy from mTOR inhibition; C. elegans only; mammalian studies needed"
Trehalose,Autophagy Activator,Disaccharide autophagy inducer,"Disaccharide that induces autophagy via TFEB activation; promotes autophagic clearance of protein aggregates and damaged organelles; mechanism distinct from mTOR inhibition",Disabled Macroautophagy;Loss of Proteostasis,"Known autophagy activator with TFEB activation; multiple preclinical studies demonstrating clearance of protein aggregates; approaching clinical use for Alzheimer's disease (Frontiers 2024 review)",Not reported,Mouse;Cell models,Preclinical / Early clinical,N/A,"Autophagy markers; protein aggregate clearance; Alzheimer's disease endpoints","Available as supplement; no dedicated aging RCTs; being explored for Alzheimer's disease (autophagy-mediated clearance of amyloid/tau); selinexor (SINE/XPO1 inhibitor) is FDA-approved for myeloma and enriches nuclear TFEB","Generally well-tolerated as dietary disaccharide; available as supplement; safety profile for chronic high-dose use not fully established","Autophagy modulators approaching clinical use for Alzheimer's disease. Frontiers in Aging Neuroscience. 2024",2024,N/A,D,"Natural disaccharide; Alzheimer's application most advanced; available as supplement"
Senolytic CAR T Cells,Immunotherapy,Engineered immune cell senolytic,"CAR T cells engineered to target senescent cell surface markers (e.g., uPAR/urokinase plasminogen activator receptor); provides immune-mediated senescent cell clearance; prophylactic and potentially one-and-done senolytic approach",Cellular Senescence;Chronic Inflammation;Stem Cell Exhaustion,"uPAR-targeting CAR T cells demonstrated prophylactic and long-lasting efficacy against age-related metabolic dysfunction in mouse models; represents a living drug approach to senescent cell clearance",Not reported,Mouse,Preclinical,N/A,N/A,"Preclinical only; demonstrated efficacy in mouse models of metabolic dysfunction; represents one-and-done senolytic approach (living drug that persists and continuously clears senescent cells)","Unknown for aging indication; CAR T therapy carries known risks from oncology: cytokine release syndrome (CRS), neurotoxicity, off-target effects; risk of autoimmunity from targeting senescent cell markers expressed on non-senescent cells","Amor C et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2024",2024,10.1038/s41586-024-07261-w,D,"One-and-done approach; living drug that persists; key concern: off-target effects on non-senescent cells expressing uPAR"
"RLS-1496 (Rubedo Life Sciences)",Senolytic,GPX4 modulator (ferroptosis-based),"GPX4 (glutathione peroxidase 4) modulator; induces ferroptosis selectively in senescent cells; exploits iron accumulation and lipid peroxide vulnerability in senescent cells; novel mechanism distinct from BCL-2/BCL-xL-based senolytics",Cellular Senescence;Chronic Inflammation,"Preclinical data supporting selective ferroptosis induction in senescent cells; first purpose-built senolytic to enter clinical development through regulatory pathway",Not reported,Mouse;Human (clinical),Phase 1 (IND cleared),N/A,"Actinic keratosis endpoints (FDA IND cleared Sept 2025); psoriasis/dermatitis/skin aging endpoints (EMA-cleared trial May 2025)","FDA IND cleared for actinic keratosis (September 2025); EMA-cleared trial for psoriasis/dermatitis/skin aging (May 2025); one of first purpose-built senolytics entering clinical development via regulatory pathway","Safety profile being established in IND-enabling studies and initial clinical trials; ferroptosis-based mechanism may have different toxicity profile than BCL-2/BCL-xL inhibitors","Rubedo Life Sciences RLS-1496 IND clearance. September 2025",2025,N/A,B,"Novel GPX4/ferroptosis mechanism; first purpose-built senolytic to clear FDA IND; dermatological applications first"
Haenkenium,Natural Senolytic,Natural polyphenol,"Natural polyphenol compound; reduces senescence markers including p16, p21, and SA-beta-gal; mechanism of senescent cell clearance under investigation",Cellular Senescence,"Reduced senescence markers (p16, p21, SA-beta-gal) in aged mice (2024); adds to natural compound senolytic arsenal alongside fisetin and quercetin",Not reported,Mouse,Preclinical,N/A,N/A,"Preclinical only; demonstrated reduction of senescence markers in aged mice; limited published data compared to other senolytics",Unknown; natural polyphenol may have favorable safety profile similar to other polyphenolic compounds,"Haenkenium senescence study in aged mice. 2024",2024,N/A,D,"Natural polyphenol; limited data; adds to growing arsenal of plant-derived senolytics"
"TAC (TERT Activating Compound)",Telomere Therapy,Epigenetic TERT de-repressor,"Small molecule identified from screen of 650,000+ compounds; epigenetically de-represses endogenous TERT gene promoter; restores physiological TERT regulation rather than constitutive overexpression; promotes neurogenesis and cognitive improvement through both telomere-dependent and transcription factor functions of TERT",Telomere Attrition;Cellular Senescence;Stem Cell Exhaustion,"TAC treatment for 6 months in aged animals (equivalent to >75 human years) led to new neuron formation (adult hippocampal neurogenesis) and significantly improved cognitive test performance; considered safer than constitutive telomerase overexpression because it restores physiological regulation",Not reported,Mouse (aged),Preclinical,N/A,N/A,"Preclinical only; discovered 2024; demonstrates that TERT reactivation reverses age-related cognitive decline through both telomere-dependent and telomere-independent (transcription factor) mechanisms","Early-stage evaluation; epigenetic de-repression approach considered safer than constitutive telomerase overexpression; restores physiological regulation; potential oncogenic risk under investigation","TAC discovery and preclinical results. High-throughput screen of 650000+ compounds. 2024",2024,N/A,D,"Screened from 650,000+ compounds; epigenetic approach considered safer than constitutive overexpression; cognitive improvement via TERT transcription factor function"